The planned inclusion aims to enhance share tradability and facilitate future access to XETRA trading.ww
Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage biopharmaceutical company pioneering novel anti-cancer therapies targeting the tumor microenvironment, announces that it intends to apply for its shares to be included in the open market of the Düsseldorf Stock Exchange, sub-segment Primary Market. The inclusion of the shares in the open market of the Düsseldorf Stock Exchange (Primary Market), in addition to the existing listings on the open markets of the Hamburg, Stuttgart, and Berlin stock exchanges, is intended to further increase the tradability of the shares for the benefit of investors, in particular through the subsequent inclusion of the shares in XETRA trading. As things stand at present, the inclusion of the shares in the open market of the Düsseldorf Stock Exchange (Primary Market) is planned for the beginning of November. The inclusion is subject to the approval of the Düsseldorf Stock Exchange and therefore cannot be predicted with certainty at this stage.
“Our goal is to make Vidac Pharma’s shares increasingly accessible to investors,” said Dr. Max Herzberg, CEO of Vidac Pharma Holding PLC. “The planned inclusion in Düsseldorf and potential XETRA trading are important steps in strengthening liquidity in the share trade and broadening our investor base.”
For more information please contact:
Max Herzberg
Vidac pharma Holding Plc
+972 54-425-7381
Visit us on social media:
LinkedIn
